JP6789579B2 - 特定の患者集団において神経変性障害を処置する方法 - Google Patents

特定の患者集団において神経変性障害を処置する方法 Download PDF

Info

Publication number
JP6789579B2
JP6789579B2 JP2018512564A JP2018512564A JP6789579B2 JP 6789579 B2 JP6789579 B2 JP 6789579B2 JP 2018512564 A JP2018512564 A JP 2018512564A JP 2018512564 A JP2018512564 A JP 2018512564A JP 6789579 B2 JP6789579 B2 JP 6789579B2
Authority
JP
Japan
Prior art keywords
subject
apoe4
tramiprosate
composition
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018512564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526407A (ja
JP2018526407A5 (enExample
Inventor
スーザン アブシャクラ，
スーザン アブシャクラ，
アイダン パワー，
アイダン パワー，
マーティン トラール，
マーティン トラール，
ジョン ヘイ，
ジョン ヘイ，
ジェレミー ユー，
ジェレミー ユー，
ピーター コシス，
ピーター コシス，
Original Assignee
アルジオン， インコーポレイテッド
アルジオン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6789579(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アルジオン， インコーポレイテッド, アルジオン， インコーポレイテッド filed Critical アルジオン， インコーポレイテッド
Publication of JP2018526407A publication Critical patent/JP2018526407A/ja
Publication of JP2018526407A5 publication Critical patent/JP2018526407A5/ja
Application granted granted Critical
Publication of JP6789579B2 publication Critical patent/JP6789579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018512564A 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法 Active JP6789579B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020161995A Division JP7128536B2 (ja) 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2018526407A JP2018526407A (ja) 2018-09-13
JP2018526407A5 JP2018526407A5 (enExample) 2019-10-24
JP6789579B2 true JP6789579B2 (ja) 2020-11-25

Family

ID=58240195

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018512564A Active JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法
JP2020161995A Active JP7128536B2 (ja) 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020161995A Active JP7128536B2 (ja) 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102412997B1 (enExample)
CN (3) CN116712423A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (2) RS68293B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (2) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960625T3 (es) 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
SI4296670T1 (sl) * 2018-08-01 2026-04-30 Alzheon, Inc. Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
PH12021553196A1 (en) * 2019-06-17 2022-11-07 Alzheon Inc Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
AU2022405026A1 (en) * 2021-12-09 2024-06-20 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease
WO2023150381A1 (en) * 2022-02-07 2023-08-10 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
CA2142300C (en) 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
EP1664601B1 (en) 2003-08-11 2016-10-12 California Institute Of Technology Microfluidic large scale integration
US20060251714A1 (en) * 2005-04-12 2006-11-09 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
NZ723884A (en) 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
ES2960625T3 (es) * 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population

Also Published As

Publication number Publication date
EP4275750C0 (en) 2026-05-06
JP7128536B2 (ja) 2022-08-31
DK3347002T3 (da) 2023-08-14
LT3347002T (lt) 2023-09-11
RS68293B1 (en) 2026-07-31
EP3347002A4 (en) 2019-04-24
EP3347002A1 (en) 2018-07-18
US20220096406A1 (en) 2022-03-31
CA2997376A1 (en) 2017-03-16
KR102547164B1 (ko) 2023-06-22
SI3347002T1 (sl) 2023-12-29
AU2016319107B2 (en) 2021-02-25
EP4275750B1 (en) 2026-05-06
PL3347002T3 (pl) 2023-11-13
FI3347002T3 (fi) 2023-08-10
US20230414541A1 (en) 2023-12-28
ES2952727T3 (es) 2023-11-03
CN116712423A (zh) 2023-09-08
HRP20230809T1 (hr) 2023-10-27
RS64481B1 (sr) 2023-09-29
MX392677B (es) 2025-03-24
EP4275750A3 (en) 2024-01-17
JP2020200352A (ja) 2020-12-17
SMT202300250T1 (it) 2023-09-06
EP4275750A2 (en) 2023-11-15
US11191742B2 (en) 2021-12-07
KR20220042480A (ko) 2022-04-05
KR102412997B1 (ko) 2022-06-23
CN108289870A (zh) 2018-07-17
MD3347002T2 (ro) 2023-10-31
HK1257874A1 (en) 2019-11-01
AU2016319107A1 (en) 2018-03-22
MX2022003128A (es) 2022-08-02
JP2025065545A (ja) 2025-04-17
CN116712422A (zh) 2023-09-08
SMT202600257T1 (it) 2026-07-16
EP3347002B1 (en) 2023-06-07
MX2018003023A (es) 2018-06-06
JP2018526407A (ja) 2018-09-13
HUE062511T2 (hu) 2023-11-28
KR20180051561A (ko) 2018-05-16
WO2017044840A1 (en) 2017-03-16
CA2997376C (en) 2024-05-14
JP2022145949A (ja) 2022-10-04
PT3347002T (pt) 2023-07-27

Similar Documents

Publication Publication Date Title
JP7128536B2 (ja) 特定の患者集団において神経変性障害を処置する方法
US11116773B2 (en) Method of treating dementia
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US11690849B2 (en) Method of treating dementia
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
EP2111862A1 (en) Pharmaceutical product for prevention and treatment of alzheimer's dementia
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
CN111902138A (zh) 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗
WO2018197383A1 (en) Idalopirdine-based combinatorial therapies of alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201027

R150 Certificate of patent or registration of utility model

Ref document number: 6789579

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250